

BIO REFERENCE LABORATORIES INC
Form 10-Q
March 11, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended January 31, 2003

Commission File Number 0-15266

BIO-REFERENCE LABORATORIES, INC.

481 Edward H. Ross Drive, Elmwood Park, NJ 07407
(201) 791-2600

New Jersey

(State of incorporation)

22-2405059

(IRS Employer Identification No.)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 11,608,583 shares of Common Stock (\$.01 par value) at March 10, 2003.

BIO-REFERENCE, LABORATORIES, INC.

FORM 10-Q

JANUARY 31, 2003

I N D E X

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Balance Sheets as of January 31, 2003 (unaudited) and October 31, 2002

1

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Statements of Operations (unaudited) for the three months ended January 31, 2003 and January 31, 2002	3
Statements of Cash Flows (unaudited) for the three months ended January 31, 2003 and January 31, 2002	4
Notes to financial statements	5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	8
Item 4. Controls and Procedures	12
PART II. OTHER INFORMATION	13
Item 6. Exhibits and Reports on Form 8-K	
Signatures	13
Certifications	

i

BIO-REFERENCE LABORATORIES, INC.

BALANCE SHEETS

ASSETS

	January 31, 2003	October 31, 2002
	(Unaudited)	
Current Assets:		
Cash and Cash Equivalents	\$ 3,926,163	\$ 3,403,365
Accounts Receivable (Net)	29,347,890	28,698,931
Inventory	1,144,263	1,080,768
Other Current Assets	1,033,094	1,183,403
	35,451,410	34,366,467
Total Current Assets	\$ 35,451,410	\$ 34,366,467
Property, Plant and Equipment	\$ 5,450,732	\$ 4,881,572
Less: Accumulated Depreciation	2,111,400	1,877,185
	3,339,332	3,004,387
Total Property, Plant and Equipment Net	\$ 3,339,332	\$ 3,004,387
Other Assets:		
Deposits	298,907	293,203
Goodwill (Net of Accumulated Amortization of \$2,401,393)	5,843,237	5,843,237
Deferred Charges (Net of Accumulated Amortization of \$2,226,826 and \$2,084,614 respectively)	2,726,010	2,868,222
Other Assets	1,039,572	1,066,658
	9,907,726	10,071,320
Total Other Assets	\$ 9,907,726	\$ 10,071,320

	January 31, 2003	October 31, 2002
	<u> </u>	<u> </u>
Total Assets	\$ 48,698,468	\$ 47,442,174
	<u> </u>	<u> </u>

The Accompanying Notes are an Integral Part of These Financial Statements.

1

BIO-REFERENCE LABORATORIES, INC.

BALANCE SHEETS

LIABILITIES AND SHAREHOLDERS' EQUITY

	January 31, 2003	October 31, 2002
	<u> </u>	<u> </u>
	(Unaudited)	
Current Liabilities:		
Accounts Payable	\$ 6,591,162	\$ 6,871,331
Salaries and Commissions Payable	1,612,145	2,420,274
Accrued Taxes and Expenses	265,332	895,340
Current Portion of Long-Term Debt	199,997	400,000
Current Portion of Leases Payable	615,749	582,751
Notes Payable	13,291,814	10,546,010
	<u> </u>	<u> </u>
Total Current Liabilities	\$ 22,576,199	\$ 21,715,706
	<u> </u>	<u> </u>
Long-Term Liabilities:		
Long-Term Portion of Leases Payable	1,289,744	1,423,659
Other Long-Term Liabilities	95,740	95,740
	<u> </u>	<u> </u>
Total Long-Term Liabilities	\$ 1,385,484	\$ 1,519,399
	<u> </u>	<u> </u>
Commitments and Contingencies		
	<u> </u>	<u> </u>
Shareholders' Equity:		
Preferred Stock \$.10 Par Value; Authorized 1,062,589 shares, None Issued	\$	\$
Series A Senior Preferred Stock, \$.10 Par Value; Authorized Issued and Outstanding 604,078 shares	60,408	60,408
Series A Junior Participating Preferred Stock, \$.10 Par Value, Authorized 3,000 Shares	\$	\$
Common Stock, \$.01 Par Value; Authorized 18,333,333 shares, Issued and Outstanding 11,608,583 shares at January 31, 2003 and 11,588,583 shares at October 31, 2002	116,086	115,886
Additional Paid-In Capital	28,565,251	28,543,576

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

	January 31, 2003	October 31, 2002
	<u> </u>	<u> </u>
Accumulated [Deficit]	(3,754,924)	(4,224,990)
	<u> </u>	<u> </u>
Totals	\$ 24,986,821	\$ 24,494,880
Deferred Compensation	(250,036)	(287,811)
	<u> </u>	<u> </u>
Total Shareholders' Equity	\$ 24,736,785	\$ 24,207,069
	<u> </u>	<u> </u>
Total Liabilities and Shareholders' Equity	\$ 48,698,468	\$ 47,442,174
	<u> </u>	<u> </u>

The Accompanying Notes are an Integral Part of These Financial Statements.

2

BIO-REFERENCE LABORATORIES, INC.

STATEMENTS OF OPERATIONS

(Unaudited)

	Three months ended January 31,	
	2003	2002
	<u> </u>	<u> </u>
Net Revenues:	\$ 23,759,027	\$ 22,294,644
	<u> </u>	<u> </u>
Cost of Services:		
Depreciation	\$ 217,357	\$ 128,084
Employee Related Expenses	6,398,976	5,742,058
Reagents and Lab Supplies	3,759,707	3,813,339
Other Cost of Services	2,810,801	3,242,653
	<u> </u>	<u> </u>
Total Cost of Services	\$ 13,186,841	\$ 12,926,134
	<u> </u>	<u> </u>
Gross Profit On Revenues	\$ 10,572,186	\$ 9,368,510
	<u> </u>	<u> </u>
General and Administrative Expenses:		
Depreciation and Amortization	\$ 159,072	\$ 163,177
Other General and Admin. Expenses	7,009,694	5,824,969
Bad Debt Expense	2,655,210	2,404,826
	<u> </u>	<u> </u>
Total General and Admin. Expenses	\$ 9,823,976	\$ 8,392,972
	<u> </u>	<u> </u>
Operating Income	\$ 748,210	\$ 975,538
	<u> </u>	<u> </u>
Other (Income) Expenses:		

	Three months ended January 31,	
	2003	2002
Interest Expense	\$ 211,811	\$ 268,585
Interest Income	(7,667)	(9,730)
Total Other Expenses Net	\$ 204,144	\$ 258,855
Income Before Tax	544,066	716,683
Provision for Income Taxes	\$ 73,999	\$ 6,935
Net Income	\$ 470,067	709,748
Net Income Per Share Basic:	\$.04	\$.06
Number of Shares Basic:	11,595,255	11,103,662
Net Income Per Share Diluted:	\$.04	\$.06
Number of Shares Diluted:	12,899,351	12,801,081

The Accompanying Notes are an Integral Part of These Financial Statements.

3

BIO-REFERENCE LABORATORIES, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

	Three months ended January 31,	
	2003	2002
Operating Activities:		
Net Income	\$ 470,067	\$ 709,748
Adjustments to Reconcile Net Income to Cash Provided by Operating Activities:		
Deferred Compensation	37,775	238,544
Depreciation and Amortization	376,429	291,261
Provision for Bad Debts	2,655,210	2,404,826
Deferred Income Tax	14,000	(42,277)
Change in Assets and Liabilities (Increase) Decrease in:		
Accounts Receivable	(3,304,169)	(3,677,792)
Other Assets	21,383	19,569
Inventory	(63,495)	32,871
Other Current Assets	136,306	(177,767)
Deferred Charges		(97,839)
Increase (Decrease) in:		
Accounts Payable and Accrued Liabilities	(1,718,306)	197,235

	Three months ended January 31,	
Net Cash Operating Activities	\$ (1,374,800)	\$ (101,621)
Investing Activities:		
Acquisition of Equipment and Leasehold Improvements	\$ (493,583)	\$ (219,319)
Financing Activities:		
Payments of Long-Term Debt	\$ (200,001)	\$ (261,818)
Payments of Capital Lease Obligations	(176,495)	(80,072)
Increase in Revolving Line of Credit	2,745,802	991,136
Proceeds from Exercise of Options	21,875	139,494
Net Cash Financing Activities	\$ 2,391,181	\$ 788,740
Net Increase in Cash and Cash Equivalents	\$ 522,798	\$ 467,800
Cash and Cash Equivalents at Beginning of Periods	\$ 3,403,365	\$ 2,355,356
Cash and Cash Equivalents at End of Periods	\$ 3,926,163	\$ 2,823,156

Supplemental Disclosures of Cash Flow Information:

Cash paid during the period for:		
Interest	\$ 141,668	\$ 237,581
Income Taxes	\$ 2,094	\$ 47,212

The Accompanying Notes are an Integral Part of These Financial Statements.

4

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

During the three month period ended January 31, 2003, the Company entered into one capital lease totaling approximately \$75,600.

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

5

BIO-REFERENCE LABORATORIES, INC.**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(Unaudited)

- (1) In the opinion of management, the accompanying unaudited consolidated financial statements reflect all adjustments (consisting only of normal adjustments and recurring accruals) which are necessary to present a fair statement of the results for the interim periods presented and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.
- (2)

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

The results of operations for the three months ended January 31, 2003 are not necessarily indicative of the results to be expected for the entire year.

- (3) The consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2002 as filed with the Securities and Exchange Commission in the Company's Annual Report on Form 10-K.
- (4) The significant accounting policies followed by the Company are set forth in Note 2 to the Company's consolidated financial statements in the October 31, 2002 Form 10-K.
- (5) Revenues are recognized at the time the services are performed. Revenues on the statements of operations are net of the following amounts for allowances and discounts.

	Three Months Ended January 31,	
	2003	2002
	(Unaudited)	
Medicare/Medicaid	\$ 16,934,942	\$ 14,626,316
Other	18,197,805	16,026,985
	\$ 35,132,747	\$ 30,653,301

A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

- (6) An allowance for contractual credits and uncollectible accounts is determined based upon a review of the reimbursement policies and subsequent collections for the different types of payors. The aggregate allowance, which is net against accounts receivable was \$28,860,516 at January 31, 2003 and \$30,045,528 at October 31, 2002 and is comprised of the following items:

	January 31, 2003	October 31, 2002
	(Unaudited)	
Contractual Credits/Discounts	\$ 22,820,499	\$ 23,010,020
Doubtful Accounts	6,040,017	7,035,508
	\$ 28,860,516	\$ 30,045,528

- (7) In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 143 "Accounting for asset retirement obligations" which requires that the

fair value of a liability for an asset retirement legal obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset. This statement is effective for fiscal years beginning after June 15, 2002.

In August 2001, FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." This statement retains the requirements of SFAS No. 121 but removes goodwill from its scope and describes a probability-weighted cash flow estimation approach in evaluating possible future cash flows to be used in impairment testing. Provisions of this statement are effective for financial statements issued for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years.

In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No. 14, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections" ("SFAS 145"). SFAS 145 among other things rescinds SFAS No. 4, "Reporting Gains and Losses from Extinguishment of Debt" ("SFAS 4"), and SFAS No. 64, "Extinguishments of Debt Made to Satisfy Sinking Fund Requirements" ("SFAS 64") and amends SFAS No. 13, "Accounting for Leases" ("SFAS 13"). This statement updates, clarifies and simplifies existing accounting pronouncements. As a result of rescinding SFAS 4 and SFAS 64, the criteria in APB No. 30, "Reporting the Results of Operations Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Event and Transactions," will be used to classify gains and losses from extinguishment of debt. SFAS 13 was amended to eliminate an inconsistency between the required accounting for sale-leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions and makes technical corrections to existing pronouncements. The provisions of SFAS 145 are effective for fiscal years beginning after May 15, 2002, with earlier application encouraged. The Company expects to adopt SFAS 145 effective November 1, 2002 and reflect any necessary reclassifications in its consolidated statements of operations. Management believes that the adoption of SFAS 145 will not have a material impact on the Company's financial position.

In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" ("SFAS 146"), which addresses the recognition, measurement, and reporting of costs associated with exit or disposal activities, and supercedes Emerging Issues Task Force ("EITF") Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)" ("EITF 94-3"). The principal difference between SFAS 146 and EITF 94-3 relates to the requirements for recognition of a liability for a cost associated with an exit or disposal activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity, including those related to employee termination benefits and obligations under operating leases and other contracts, be recognized when the liability is incurred, and not necessarily the date of an entity's commitment to an exit plan, as under EITF 94-3. SFAS 146 also establishes that the initial measurement of a liability recognized under SFAS 146 be based on fair value. The provisions of SFAS 146 are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged.

In December 2002, FASB Statement No. 148 "Accounting for Stock Based Compensation Transition and Disclosure" was issued as an amendment of FASB Statement No. 123. Provisions of Statement No. 148 provide for alternate methods of transition for a voluntary change to the fair

value based method of accounting for stock-based employee compensation. In addition, Statement No. 148 amends the disclosure requirements of Statement No. 123 to require prominent disclosure in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reporting results. Statement No. 148 is effective for entities with a fiscal year ending after December 15, 2002. Certain disclosure requirement under Statement No. 148 are effective for financial reports containing condensed financial statements for interim periods beginning after December 15, 2002.

(8)

At January 31, 2003, the Company had a gross deferred tax asset of approximately \$800,000 and a valuation allowance of approximately \$500,000 related to the asset, a decrease of \$400,000 from October 31, 2002. The net deferred tax asset balance of approximately \$300,000 primarily relates to net operating loss carry forwards and is reported under the "Other Current Assets" caption.

(9)

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

In January 2002, we amended our revolving loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is now the lesser of (i) \$25,000,000 or (ii) 50% of our qualified accounts receivable (as defined in the agreement). Interest on advances will be subject to the prime rate or Eurodollar rate of interest plus an additional interest percentage. The additional interest percentage charges on borrowings range from 1% to 3% and are determined based upon certain financial ratios achieved by the Company. During fiscal 2002, the Company had elected to have \$8,000,000 of the total advances outstanding converted into a Eurodollar rate loan with a variable interest rate of 3.20% at January 31, 2003. The remaining outstanding advances during that period were subject to the prime rate of interest. At January 31, 2003, advances of \$5,291,814 were subject to interest at the prime rate. The credit line is collateralized by substantially all of our assets and the assignment of a \$4,000,000 insurance policy on the life of the president of our Company. The line of credit is currently available through September 2004. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, various financial ratios and insurance coverage. As of January 31, 2003, we were utilizing approximately \$13,292,000 of this credit facility and had \$7,399,957 of available unused credit under this revolving loan agreement.

(10)

In the normal course of its business, the Company is exposed to a number of asserted and unasserted potential claims. In the opinion of management, the resolution of these matters will not have a material adverse effect on the Company's financial position or results of operations.

At November 1, 1998, the Company was being represented by counsel in connection with various reviews being conducted by the Company's Medicare carrier. One review involved overpayments that occur in the normal course of business. The Company remitted approximately \$75,000 to Medicare in connection with this matter. At October 31, 2002, the Company had established a reserve of \$154,000 on its financial statements for the remaining liability. In January 2003, Medicare determined that the remaining overpayment was \$78,684 and interest on this amount was \$2,392. The total amount of \$81,076 was remitted by the Company to Medicare in January 2003, bringing the matter to a close.

8

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS RESULTS OF OPERATIONS COMPARISON OF FIRST QUARTER 2003 VS FIRST QUARTER 2002

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains historical information as well as forward-looking statements. Statements looking forward in time are included in this Quarterly Report pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to be materially different from any future performance suggested herein. For a further discussion concerning risks to our business, the results of our operations and our financial condition, reference is made to our Annual Report on Form 10-K for the year ended October 31, 2002.

OVERVIEW:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of revenues and expenses during the reporting period. While many aspects of our business are subject to complex federal, state and local regulations, the accounting for our business is generally straightforward. Our revenues are primarily comprised of a high volume of relatively low dollar transactions, and about 46% of all our costs consist of employee compensation and benefits. Revenues are recognized at the time the services are performed and are reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered including prospectively determined adjustments under reimbursement agreements with third-party payors. These adjustments are accrued on an estimated basis in the period the services are rendered and adjusted in future periods as final settlements are determined. These estimates are reviewed and adjusted, if warranted, by senior management on a monthly basis. We believe that our estimates and assumptions are correct; however, several factors could cause actual results to differ materially from those currently anticipated due to a number of factors:

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

our failure to integrate newly acquired businesses (if any) and the cost related to such integration.

our failure to obtain and retain new customers and alliance partners, or a reduction in tests ordered or specimens submitted by existing customers.

adverse results from investigations of clinical laboratories by the government, which may include significant monetary damages and/or exclusion from the Medicare and Medicaid programs.

loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA-88, or those of Medicare, Medicaid or other federal, state or local agencies.

future changes in federal, state, local and third party payor regulations or policies (or in the interpretation of current regulations) affecting governmental and third-party reimbursement for clinical laboratory testing.

failure to comply with the Federal Occupational Safety and Health Administration requirements and the recently passed Needlestick Safety and Prevention Act.

failure to comply with HIPAA, which could result in significant fines as well as substantial criminal penalties.

9

changes in payor mix.

failure to maintain our days sales outstanding levels.

increased competition, including price competition.

our ability to attract and retain experienced and qualified personnel.

adverse litigation results.

We utilize diluted earnings per share ("EPS") on pre-tax income as a performance indicator rather than the traditional EPS calculation on an after tax basis. This pre-tax EPS takes out the nuance of tax differences caused by large net operating loss carryforwards which create benefits (which we used in the past) and tax expense (which we expect in the future). Our pre-tax EPS on a diluted basis for the first quarter of fiscal years 2002 and 2003 were \$.06 and \$.04, respectively.

NET REVENUES:

We had net revenues for the three month period ended January 31, 2003 of \$23,759,027 as compared to \$22,294,644 for the three month period ended January 31, 2002. This represents a 7% increase in net revenues. This increase is due primarily to a 6% increase in the number of patients serviced. The first quarter of the current fiscal year was extremely bad as far as the weather was concerned. The Mid-Atlantic states had its first snowfall in November and had four snow occurrences during December 2002.

The number of patients serviced during the quarter ended January 31, 2003 was 477,841 which was 6% greater when compared to the prior fiscal year's quarter ended January 31, 2002. Net revenue per patient for the quarter ended January 31, 2003 was \$50.10 compared to net revenue per patient for the quarter ended January 31, 2002 of \$49.59.

COST OF SERVICES:

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Cost of Services increased from \$12,926,134 for the three month period ended January 31, 2002 to \$13,186,841 for the three month period ended January 31, 2003, an increase of \$260,707 or 2%. This increase is substantially less than the 7% increase in net revenues.

GROSS PROFITS:

Gross profit on net revenues increased 13% to \$10,572,186 for the three month period ended January 31, 2003 compared to \$9,368,510 for the same period ended January 31, 2002. Gross Profit margin increased approximately 3% in the current period reflecting decreased direct costs in relation to net revenues.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the three month period ended January 31, 2003 were \$9,823,976 compared to \$8,392,972 for the three month period ended January 31, 2002. This represents an increase of \$1,431,004 (17%) which was caused primarily by an increase of \$349,025 (170%) in insurance expense (influenced by several factors including the 9/11 WTC attack), a \$250,384 (10%) increase in Bad Debt Expense, a \$128,248 (85%) increase in Data Processing salaries, and a \$54,841 (46%) increase in legal fees. Other cost increases were primarily due to the increase in revenue for the three month period ended January 31, 2003.

10

INTEREST EXPENSE:

Interest expense decreased from \$268,585 for the three month period ended January 31, 2002 to \$211,811 for the three month period ended January 31, 2003, a decrease of \$56,774. This decrease is due to a decline in the variable interest rates associated with the PNC Bank line of credit utilized by the Company. Management believes that this trend will not continue in the future due to the continued use of our revolving line of credit to fund our expansion and growth and the expectation that interest rates will not substantially decrease.

INCOME:

We realized net income of \$470,067 for the period ended January 31, 2003, compared to net income of \$709,748 for the same period ended January 31, 2002. Pre-tax income for the period ended January 31, 2003 was \$544,066, compared to \$716,683 for the same period ended January 31, 2002, a decrease of \$172,617 (24%) and was caused primarily by the increase in general and administrative expenses in relation to the increase in net revenue. The provision for income taxes increased from \$6,935 for the period ended January 31, 2002 to \$73,999 for the period ended January 31, 2003. This increase was anticipated due to the full utilization of certain state tax loss carry-forwards in fiscal 2002.

LIQUIDITY AND CAPITAL RESOURCES:

For the Quarter Ended January 31, 2003

Our working capital at January 31, 2003 was approximately \$12,875,000 as compared to approximately \$12,651,000 at October 31, 2002, an increase of \$224,000. Our cash position increased by approximately \$523,000 during the current period. We borrowed approximately \$2,746,000 in short term debt and repaid approximately \$376,000 in existing debt. We had current liabilities of approximately \$22,591,000 at January 31, 2003. We utilized approximately \$1,375,000 in cash from operations, compared to cash utilized from operations for the quarter ended January 31, 2002 of approximately \$102,000.

Accounts receivable, net of allowance for doubtful accounts, totaled approximately \$29,348,000 at January 31, 2003, an increase of approximately \$649,000 from October 31, 2002, or 2%. This increase was primarily attributable to increased revenue. Cash collected during the three month period ended January 31, 2003 increased 9% over the comparable three month period.

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. We have significant receivable balances with government payors and various insurance carriers. Generally, we do not require collateral or other security to support customer receivables, however, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable. While we maintain what we believe to be an adequate allowance for doubtful accounts, there can be no assurance that our ongoing review of accounts receivable will not result in the need for additional reserves. Such additional reserves could have a material impact on our financial position and results of operations.

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

In January 2002, we amended our revolving loan agreement with PNC Bank. The maximum amount of the credit line available to us is now the lesser of (i) \$25,000,000 or (ii) 50% of our qualified accounts receivable (as defined in the agreement). Interest on advances will be subject to the prime rate or Eurodollar rate of interest plus an additional interest percentage. The additional interest percentage charges on borrowings range from 1% to 3% and are determined based upon certain financial ratios achieved by the Company. During fiscal 2002, the Company had elected to have \$8,000,000 of the total advances outstanding converted into a Eurodollar rate loan with a variable interest rate of 3.20% at January 31, 2003. The remaining outstanding advances during that period were subject to the prime rate of interest. At January 31, 2003, advances of \$5,291,814 were subject to

11

interest at the prime rate. The credit line is collateralized by substantially all of our assets and the assignment of a \$4,000,000 insurance policy on the life of the president of our Company. The line of credit is currently available through September 2004. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, various financial ratios and insurance coverage. As of January 31, 2003, we were utilizing approximately \$13,292,000 of this credit facility and had \$7,399,957 of available unused credit under this revolving loan agreement.

At November 1, 1998, the Company was being represented by counsel in connection with various reviews being conducted by the Company's Medicare carrier. One review involved overpayments that occur in the normal course of business. The Company remitted approximately \$75,000 to Medicare in connection with this matter. At October 31, 2002, the Company had established a reserve of \$154,000 on its financial statements for the remaining liability. In January 2003, Medicare determined that the remaining overpayment was \$78,684 and interest on this amount was \$2,392. The total amount of \$81,076 was remitted by the Company to Medicare in January 2003, bringing the matter to a close.

We intend to expand our laboratory operations through aggressive marketing while also diversifying into related medical fields through acquisitions. These acquisitions may involve cash, notes, common stock, and/or combinations thereof.

We have various employment and consulting agreements with commitments totaling approximately \$6,282,000 over the next five years of which approximately \$2,968,000 is due during fiscal 2003. We have capitalized leases with commitments totaling approximately \$2,006,000 of which approximately \$748,000 is due during fiscal 2003. We have operating leases with commitments totaling approximately \$9,380,000 of which approximately \$3,444,000 is due during fiscal 2003.

Our cash balance at January 31, 2003 totaled approximately \$3,926,000 as compared to approximately \$3,403,000 at October 31, 2002. We believe that our cash position, the anticipated cash generated from future operations, and the availability of our credit line with PNC Bank, will meet our anticipated cash needs in fiscal 2003.

Impact of Inflation To date, inflation has not had a material effect on our operations.

New Authoritative Pronouncements

The Financial Accounting Standards Board ("FASB") has issued Statement No. 143 "Accounting for Asset Retirement Obligations" in June 2001, which requires that the fair value of a liability for an asset retirement legal obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset. This statement is effective for fiscal years beginning after June 15, 2002.

In August 2001, FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." This statement retains the requirements of SFAS No. 121 but removes goodwill from its scope and describes a probability-weighted cash flow estimation approach in evaluating possible future cash flows to be used in impairment testing. Provisions of this statement are effective for financial statements issued for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years.

In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No. 14, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections" (SFAS 145). SFAS 145 among other things rescinds SFAS No. 4, "Reporting Gains and Losses from Extinguishment of Debt" ("SFAS 4"), and SFAS No. 64, "Extinguishments of Debt Made to Satisfy Sinking Fund Requirements" ("SFAS 64") and amends SFAS No. 13, "Accounting for Leases" ("SFAS 13"). This statement updates, clarifies and simplifies existing accounting pronouncements. As a result of rescinding SFAS 4 and SFAS

12

64, the criteria in APB No. 30, "Reporting the Results of Operations Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Event and Transactions," will be used to classify gains and losses from extinguishment of debt. SFAS 13 was amended to eliminate an inconsistency between the required accounting for sale-leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions and makes technical corrections to existing pronouncements. The provisions of SFAS 145 are effective for fiscal years beginning after May 15, 2002, with earlier application encouraged. The Company adopted SFAS 145 effective November 1, 2002 and made the necessary reclassifications in its consolidated statements of operations. Management believes that the adoption of SFAS 145 will not have a material impact on the Company's financial position.

In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" ("SFAS 146"), which addresses the recognition, measurement, and reporting of costs associated with exit or disposal activities, and supercedes Emerging Issues Task Force ("EITF") Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)" ("EITF 94-3"). The principal difference between SFAS 146 and EITF 94-3 relates to the requirements for recognition of a liability for a cost associated with an exit or disposal activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity, including those related to employee termination benefits and obligations under operating leases and other contracts, be recognized when the liability is incurred, and not necessarily the date of an entity's commitment to an exit plan, as under EITF 94-3. SFAS 146 also establishes that the initial measurement of a liability recognized under SFAS 146 be based on fair value. The provisions of SFAS 146 are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged.

In December 2002, FASB Statement No. 148 "Accounting for Stock-Based Compensation Transition and Disclosure" was issued as an amendment of FASB Statement No. 123. Provisions of Statement No. 148 provide for alternate methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, Statement No. 148 amends the disclosure requirements of Statement No. 123 to require prominent disclosure in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reporting results. Statement No. 148 is effective for entities with a fiscal year ending after December 15, 2002. Certain disclosure requirement under Statement No. 148 are effective for financial reports containing condensed financial statements for interim periods beginning after December 15, 2002.

Item 4 CONTROLS AND PROCEDURES

(a) *Explanation of disclosure controls and procedures.* The Company's chief executive officer and its chief financial officer after evaluating the effectiveness of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-14(c) and 15-d-14(c) as of a date within 90 days of the filing date of this quarterly report (the "Evaluation Date") have concluded that as of the Evaluation Date, the Company's disclosure controls and procedures were adequate and effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities, particularly during the period in which this quarterly report was being prepared.

(b) *Changes in internal controls.* There were no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's disclosure controls and procedures subsequent to the Evaluation Date, nor any significant deficiencies or material weaknesses in such disclosure controls and procedures requiring corrective actions. As a result, no corrective actions were taken.

PART II OTHER INFORMATION

Item 6 EXHIBITS AND REPORTS ON FORM 8-K

(a) None.

(b) The Company filed no reports on Form 8-K during the quarter ended January 31, 2003

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BIO-REFERENCE LABORATORIES, INC.
(Registrant)**

/s/ MARC D. GRODMAN, M.D.

Marc D. Grodman, M.D.
President

/s/ SAM SINGER

Sam Singer
Chief Financial and Accounting Officer

Date: March 10, 2003

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the "Company") do hereby certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended January 31, 2003;

(2) Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

(3) Based on my knowledge, the financial statements and other financial information included in this quarterly report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Company as of, and for, the period presented in this quarterly report;

(4) The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and we have:

- (a) designed such disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report was being prepared;
- (b) evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
- (c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

(5) The Company's other certifying officer and I have disclosed, based on our most recent evaluation, to the Company's auditors and the audit committee of the Company's board of directors:

- (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Company's ability to record, process, summarize and report financial data and have identified for the Company's auditors any material weaknesses in internal controls; and
- (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls; and

(6) The Company's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Dated: March 5, 2003

/s/ MARC D. GRODMAN

Marc D. Grodman
Chief Executive Officer
Bio-Reference Laboratories, Inc.

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the "Company") do hereby certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended January 31, 2003;
- (2) Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
- (3) Based on my knowledge, the financial statements and other financial information included in this quarterly report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Company as of, and for, the period presented in this quarterly report;
- (4) The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and we have:
 - (a) designed such disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report was being prepared;
 - (b) evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - (c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
- (5) The Company's other certifying officer and I have disclosed, based on our most recent evaluation, to the Company's auditors and the audit committee of the Company's board of directors:

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

- (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Company's ability to record, process, summarize and report financial data and have identified for the Company's auditors any material weaknesses in internal controls; and
- (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls; and

(6) The Company's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Dated: March 5, 2003

/s/ SAM SINGER

Sam Singer
Chief Financial Officer
Bio-Reference Laboratories, Inc.

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**

I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (a) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended January 31 2003, which this certification accompanies (the "Periodic Report"), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
- (b) based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 5, 2003

/s/ MARC D. GRODMAN

Marc D. Grodman
Chief Executive Officer
Bio-Reference Laboratories, Inc.

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**

I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (a)

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

the Quarterly Report on Form 10-Q of the Company for the quarterly period ended January 31 2003, which this certification accompanies (the "Periodic Report"), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(b)

based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 5, 2003

/s/ SAM SINGER

Sam Singer
Chief Financial Officer
Bio-Reference Laboratories, Inc.

QuickLinks

[BIO-REFERENCE LABORATORIES, INC. FORM 10-Q JANUARY 31, 2003](#)

[INDEX](#)

[BIO-REFERENCE LABORATORIES, INC. BALANCE SHEETS](#)

[ASSETS](#)

[BIO-REFERENCE LABORATORIES, INC. BALANCE SHEETS](#)

[LIABILITIES AND SHAREHOLDERS' EQUITY](#)

[BIO-REFERENCE LABORATORIES, INC. STATEMENTS OF OPERATIONS \(Unaudited\)](#)

[BIO-REFERENCE LABORATORIES, INC. STATEMENTS OF CASH FLOWS \(Unaudited\)](#)

[BIO-REFERENCE LABORATORIES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS \(Unaudited\)](#)

[Item 2.](#)

[MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS RESULTS OF OPERATIONS COMPARISON OF FIRST QUARTER 2003 VS FIRST QUARTER 2002](#)

[Item 4 CONTROLS AND PROCEDURES](#)

[PART II OTHER INFORMATION](#)

[Item 6 EXHIBITS AND REPORTS ON FORM 8-K](#)

[SIGNATURES](#)

[CHIEF EXECUTIVE OFFICER CERTIFICATION](#)

[CHIEF FINANCIAL OFFICER CERTIFICATION](#)

[CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002](#)

[CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002](#)